Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1962 1
1967 1
1968 2
1972 1
1975 2
1976 2
1977 3
1978 10
1979 4
1980 8
1981 9
1982 5
1983 6
1984 4
1985 9
1986 7
1987 5
1988 10
1989 5
1990 15
1991 15
1992 18
1993 13
1994 14
1995 25
1996 13
1997 19
1998 15
1999 14
2000 12
2001 33
2002 28
2003 29
2004 33
2005 35
2006 32
2007 48
2008 36
2009 40
2010 57
2011 62
2012 59
2013 67
2014 87
2015 99
2016 109
2017 105
2018 99
2019 100
2020 142
2021 172
2022 143
2023 125
2024 146
2025 157
2026 153

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,212 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Rugo HS, et al. Among authors: d cruz cm. ESMO Open. 2024 Sep;9(9):103697. doi: 10.1016/j.esmoop.2024.103697. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241495 Free PMC article. Clinical Trial.
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group. Oliveira M, et al. Among authors: d cruz c. Lancet Oncol. 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. Lancet Oncol. 2024. PMID: 39214106 Clinical Trial.
International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council.
Choon SE, van de Kerkhof P, Gudjonsson JE, de la Cruz C, Barker J, Morita A, Romiti R, Affandi AM, Asawanonda P, Burden AD, Gonzalez C, Marrakchi S, Mowla MR, Okubo Y, Oon HH, Terui T, Tsai TF, Callis-Duffin K, Fujita H, Jo SJ, Merola J, Mrowietz U, Puig L, Thaçi D, Velásquez M, Augustin M, El Sayed M, Navarini AA, Pink A, Prinz J, Turki H, Magalhães R, Capon F, Bachelez H; IPC Pustular Psoriasis Working Group. Choon SE, et al. Among authors: de la cruz c. JAMA Dermatol. 2024 Jul 1;160(7):758-768. doi: 10.1001/jamadermatol.2024.0915. JAMA Dermatol. 2024. PMID: 38691347
Pediatric Chagas disease.
Garcia-Bournissen F, Cruz C, Altcheh J. Garcia-Bournissen F, et al. Among authors: cruz c. CMAJ. 2026 Feb 16;198(6):E226. doi: 10.1503/cmaj.153680-l. CMAJ. 2026. PMID: 41702619 Free PMC article. No abstract available.
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.
Schmid P, McArthur HL, Cortés J, Xu B, Cardoso F, Casalnuovo M, Demirci U, Freitas-Junior R, Ghosh J, Hegg R, Iwata H, Karnaukhov I, Chuken YL, Nechaeva M, Robson ME, Villalobos-Valencia R, Yamashita T, Zurawski B, de Bruin EC, Grinsted L, D'Cruz C, Foxley A, Park YH. Schmid P, et al. Among authors: d cruz c. Ann Oncol. 2026 May;37(5):650-662. doi: 10.1016/j.annonc.2025.12.012. Epub 2025 Dec 19. Ann Oncol. 2026. PMID: 41422862 Free article. Clinical Trial.
Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.
Jhaveri K, Rugo HS, Cortés J, Oliveira M, Howell SJ, Dalenc F, Gomez HL, Hu X, Krivorotko P, Loibl S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Zhukova L, Nardone A, Wadsworth I, D'Cruz C, Wantenaar T, Das D, de Bruin EC, Turner NC. Jhaveri K, et al. Among authors: d cruz c. Clin Cancer Res. 2026 Aug 14;32(16):3599-3607. doi: 10.1158/1078-0432.CCR-25-2965. Clin Cancer Res. 2026. PMID: 42154572 Free PMC article. Clinical Trial.
Lactic Acid in Tumour Biology.
Cruz C, Barba I. Cruz C, et al. Metabolites. 2026 Jan 15;16(1):75. doi: 10.3390/metabo16010075. Metabolites. 2026. PMID: 41590683 Free PMC article. Review.
Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.
Lambert N, El Moussaoui M, Le Guilloux A, Joly M, Del Carmen Garcia Martearena M, Mainardi I, Bernard-Valnet R, Pinnetti C, Antinori A, Mondi A, Greve KF, Brousse X, Westendorp WF, Wijburg MT, Grote-Levi L, Möhn N, Pourcher V, Gressens SB, Cruz CV, van Pesch V, Vidal M, Redor A, Makinson A, Konitsioti AM, Hoellinger B, Nitsch L, Ney DE, Faure E, Alstadhaug KB, Martinot M, Genderini FG, Legras J, Garzaro M, Blanchi S, Gazaignes S, Borrelli S, Patrat-Delon S, Vydrář D, Nicolas-Vullierme P, Moutel M, Cartau T, London F, Cabié A, Bouiller K, Montcuquet A, Loubet P, Sayre N, Le Marechal M, Clifford DB, Skripuletz T, Brouwer MC, Bodilsen J, Du Pasquier R, Cortese I, Cinque P, Sommet A, Martin-Blondel G. Lambert N, et al. Among authors: cruz cv. Brain. 2026 Jun 18:awag213. doi: 10.1093/brain/awag213. Online ahead of print. Brain. 2026. PMID: 42314166
2,212 results